The insertion/deletion polymorphism of the angiotensin-converting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 10, Issue 2, 2009, Pages 109-114

  Nikzamir, Abdolrahim ^a   Esteghamati, Alireza ^b   Feghhi, Mostafa ^a   Nakhjavani, Manouchehr ^b   Rashidi, Armin ^b   Reza, Javad Zavar ^c  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b UNIVERSITY OF TEHRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Albuminuria; Angiotensin converting enzyme; Diabetes; Nephropathy; Polymorphism; Progression

Indexed keywords

CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; INSULIN; ORAL ANTIDIABETIC AGENT;

ADULT; ALBUMINURIA; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; FEMALE; GENE DELETION; GENE FREQUENCY; GENE INSERTION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; IRAN; MACROALBUMINURIA; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; POLYMERASE CHAIN REACTION;

ALBUMINURIA; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; GENE DELETION; HUMANS; IRAN; MALE; MUTAGENESIS, INSERTIONAL; PEPTIDYL-DIPEPTIDASE A;

EID: 67650495736     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320309104872     Document Type: Article

References (31)

1. Rigat B., Hubert C., Alhenc-Gelas F. et al. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest 1990;86:1343-6.
2. Tiret L., Rigat B., Visvikis S. et al. Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels. Am J Hum Genet 1992;51:197-205.
3. Jacobsen PK Preventing end stage renal disease in diabetic patients - genetic aspect (part I). J Renin Angiotensin Aldosterone Syst 2005;6:1-14.
4. Investigators for HOPE study. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: Results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
5. Brenner BM, Cooper ME, de Zeeuw D. et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
6. Ruggenenti P., Bettinaglio P., Pinares F., Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol 2008;3:1511-25.
7. Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care 2003;26:S5-20.
8. Aiello LP, Gardner TW, King GL et al. Diabetic retinopathy. Diabetes Care 1998;21:143-56.
9. Nakhjavani M., Esfahanian F., Jahanshahi A. et al. The relationship between the insertion/deletion polymorphism of the ACE gene and hypertension in Iranian patients with type 2 diabetes. Nephrol Dial Transplant 2007;22:2549-53.
10. Lieberman J. Elevation of serum angiotensin-converting-enzyme (ACE) level in sarcoidosis. Am J Med 1975;59:365-72.
11. Lieberman J. The specificity and nature of serum-angiotensin-converting enzyme (serum ACE) elevations in sarcoidosis. Ann N Y Acad Sci 1976;278:488-97.
12. Feghhi M., Nikzamir A., Esteghamati A., Farahi F., Nakhjavani M., Rashidi A. The relationship between angiotensin-converting enzyme insertion/deletion polymorphism and proliferative retinopathy in type 2 diabetes. Diabetes Res Clin Pract 2008;81:1-4.
13. Marre M., Bernadet P., Gallois Y. et al. Relationships between angiotensin I converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes 1994;43:384-8.
14. Doria A., Warram JH, Krolewski AS Genetic predisposition to diabetic nephropathy: Evidence for a role of the angiotensin I converting enzyme gene. Diabetes 1994;43:690-5.
15. Marre M., Jeunemaitre X., Gallois Y. et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: Genetique de la Nephropathie Diabetique (GENEDIAB) study group. J Clin Invest 1997;99:1585-95.
16. Hadjadj S., Belloum R., Bouhanick B. et al. Prognostic value of angiotensin-I converting enzyme I/D polymorphism for nephropathy in type 1 diabetes mellitus: A prospective study. J Am Soc Nephrol 2001;12:541-9.
17. Schmidt S., Schöne N., Ritz E. Association of ACE gene polymorphism and diabetic nephropathy? The Diabetic Nephropathy Study Group. Kidney Int 1995;47:1176-81.
18. Pfohl M., Frost D., Koch M. et al. Lack of association between the insertion/deletion polymorphism of the angiotensin-converting-enzyme gene and diabetic nephropathy in IDDM patients. Horm Metab Res 1998;30:276-80.
19. Schmidt S., Strojek K., Grzeszczak W., Bergis K., Ritz E. Excess of DD homozygotes in haemodialysed patients with type II diabetes. The Diabetic Nephropathy Study Group. Nephrol Dial Transplant 1997;12:427-9.
20. Arfa I., Abid A., Nouira S. et al. Lack of association between the angiotensin-converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst 2008;9:32-6.
21. Hadjadj S., Gallois Y., Alhenc-Gelas F. et al. Angiotensin-I-converting enzyme insertion/deletion polymorphism and high urinary albumin concentration in French type 2 diabetes patients. Diabet Med 2003;20:677-82.
22. Mizuiri S., Hemmi H., Inoue A. et al. Angiotensin-converting-enzyme polymorphism and development of diabetic nephropathy in non-insulin-dependent diabetes mellitus. Nephron 1995;70:455-9.
23. Okuno S., Utsugi T., Ohno T. et al. Angiotensin-converting enzyme gene polymorphism as a potent risk factor for developing microalbuminuria in Japanese patients with type 2 diabetes mellitus: A 9-year follow-up study. J Int Med Res 2003;31:290-8.
24. Hsieh MC, Lin SR, Hsieh TJ et al. Increased frequency of angiotensin-converting enzyme DD genotype in patients with type 2 diabetes in Taiwan. Nephrol Dial Transplant 2000;15:1008-13.
25. Jacobsen PK, Tarnow L., Parving HH Time to consider ACE insertion/ deletion genotypes and individual renoprotective treatment in diabetic nephropathy? Kidney Int 2006;69:1293-5.
26. Ha SK, Park HC, Park HS et al. ACE gene polymorphism and progression of diabetic nephropathy in Korean type 2 diabetic patients: Effect of ACE gene DD on the progression of diabetic nephropathy. Am J Kidney Dis 2003;41:943-9.
27. So WY, Ma RC, Ozaki R. et al. Angiotensin-converting enzyme (ACE) inhibition in type 2, diabetic patients - interaction with ACE insertion/ deletion polymorphism. Kidney Int 2006;69:1438-43.
28. Moriyama T., Kitamura H., Ochi S. et al. Association of angiotensin I-converting enzyme gene polymorphism with susceptibility to antiproteinuric effect of angiotensin I-converting enzyme inhibitors in patients with proteinuria. J Am Soc Nephrol 1995;6:1676-8.
29. Ha SK, Yong Lee S., Su Park H. et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus. Nephrol Dial Transplant 2000;15:1617-23.
30. Scharplatz M., Puhan MA, Steurer J. et al. Does the angiotensin-converting enzyme (ACE) gene insertion/deletion polymorphism modify the response to ACE inhibitor therapy? A systematic review. Curr Control Trials Cardiovasc Med 2005;6:16-27.
31. Nikzamir A., Nakhjavani M., Esteghamati A., Rashidi A. Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition. Nephrol Dial Transplant 2008;23:1274-7.